SRX3207 - 半岛电竞官方网址

您好，欢迎来到半岛电竞官方网址！ [ 登录] [ 免费注册]

立即咨询

咨询类型：

采购售后

*姓名：

*电话：

*单位：

Email：

*留言内容：

请详细说明您的需求。

*验证码：

SRX3207

本半岛bd体育手机客户端不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2254693-15-5

包装与价格：

半岛bd体育手机客户端介绍

SRX3207 是具有口服活性的、首创的 Syk/PI3K 双抑制剂，其对 Syk 和 PI3Kα 的 IC50 值分别为 10.7 nM 和 861 nM。SRX3207 缓解抗肿瘤免疫抑制。

Cas No.	2254693-15-5
分子式	C₂₉H₂₉N₇O₃S
分子量	555.65
溶解度	DMSO : 5 mg/mL (9.00 mM; Need ultrasonic)
储存条件	Store at -20°C
General tips	For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition	Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request
半岛bd体育手机客户端描述	SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor, with IC50 values of 10.7 nM and 861 nM for Syk and PI3Kα, respectively. SRX3207 relieves tumor immunosuppression[1][2]. SRX3207 (10 μmol/L) is able to block p-AKT at concentration[1].SRX3207 has sufficient solubility in water (43 μmol/L)[1]. SRX3207 (10 mg/kg, orally) increases antitumor immune response[1]. [1]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Molecular Cancer Therapeutics. 2020. [2]. Shweta Joshi, et al. Macrophage Syk-PI3Kγ Inhibits Antitumor Immunity: SRX3207, a Novel Dual Syk-PI3K Inhibitory Chemotype Relieves Tumor Immunosuppression. Mol Cancer Ther. 2020 Mar;19(3):755-764.